Closing the Loop in People With Type 1 Diabetes (CLEAR Phase 2)
Type 1 Diabetes
About this trial
This is an interventional treatment trial for Type 1 Diabetes
Eligibility Criteria
Inclusion Criteria: The participant has type 1 diabetes as defined by WHO for at least 1 year The participant is aged 13 to 19 years (inclusive) (Phase 2) The participant will have been on an insulin pump for at least 3 months with good knowledge of insulin self-adjustment The participant is treated with one of the rapid acting or ultra-rapid acting insulin analogues (Insulin Aspart, faster acting insulin Aspart, Insulin Lispro, ultra-rapid Lispro insulin or Insulin Glulisine) 6. HbA1c ≥7.5% (58mmol/mol) based on analysis from local laboratory 7. The participant is willing to wear closed-loop devices 8. The participant is willing to follow study specific instructions 9. Female participants of child bearing age must have a negative urine-HCG pregnancy test at screening and should be using effective contraception if sexually active. Exclusion Criteria: Any physical or psychological disease or condition likely to interfere with the normal conduct of the study and interpretation of the study results Known or suspected allergy against insulin Total daily insulin dose more than or equal to 2 IU/kg/day Use of a closed-loop system within the past 30 days Participant is pregnant or breast feeding or planning pregnancy within next 12 months Severe visual impairment Severe hearing impairment Lack of reliable telephone facility for contact Participant not proficient in English
Sites / Locations
- Addenbrooke's HospitalRecruiting
- Alder Hey Children's Hospital
- Manchester Royal Infirmary
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Fully closed-loop system with age-approved ultra-rapid insulin
Standard insulin pump therapy with CGM
The fully closed-loop system (CamAPS HX) will consist of: Mylife YpsoPump insulin pump (Ypsomed, Burgdorf, Switzerland). Freestyle Libre 3 real-time CGM sensor (Abbott, Diabetes Care, CA, USA) Android smartphone hosting CamAPS HX App with the Cambridge model predictive control algorithm. Cloud upload system to review CGM/insulin data. Participants will use ultra-rapid insulin aspart in the closed-loop system.
Participants will use their own insulin pump and usual insulin throughout this study period. The CGM will be the Freestyle Libre 3 real-time CGM sensor (Abbott, Diabetes Care, CA, USA).